Generic Drugs and Preemption in the Wake of Wyeth v. Levine


There is a rapidly growing split of authority among courts as to whether FDA regulation of generic drug labeling preempts state-law failure-to-warn claims. This article examines the continuing viability of a preemption defense in pharmaceutical product liability cases alleging the defective labeling of generic drugs in the wake of Levine.

LOADING PDF: If there are any problems, click here to download the file.